New hope for tough leukemia: experimental therapy CT1390B enters first human tests
NCT ID NCT07441980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, CT1390B, in 18 adults whose acute myeloid leukemia has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink or clear the cancer. Participants must be between 18 and 70 years old and have a specific marker (CLL-1 positive) on their leukemia cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral drug targets Tough-to-Treat leukemia
- Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
- Can lab tests guide better AML treatment choices?
- Experimental CAR-T therapy targets tough leukemia
- New drug CLN-049 aims to fight Hard-to-Treat blood cancers
- Experimental CAR-T therapy takes on tough leukemia